Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Plasma protein fraction human** is a sterile, plasma-derived colloid solution for intravenous infusion composed primarily of human albumin with smaller quantities of alpha and beta globulins. It expands intravascular plasma volume through the colloid osmotic pressure of its protein content and is used for plasma-volume replacement in shock caused by burns, crushing injuries, abdominal emergencies, hemorrhage, and other settings with predominant plasma-fluid loss. The currently labeled United States product, **Plasmanate**, contains 5 g selected plasma proteins per 100 mL and is approximately iso-oncotic and isotonic with normal plasma. ([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=679bbaf2-b082-5948-8400-ece5340eabc1))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on plasma protein fraction human.